MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
BCRX BioCryst Pharmaceuticals
- 7.570
- +0.180+2.44%
Close Dec 20 16:00 ET
- 7.630
- +0.060+0.79%
Post 20:05 ET
1.57BMarket Cap-12.41P/E (TTM)
7.600High7.250Low5.07MVolume7.250Open7.390Pre Close38.10MTurnover2.62%Turnover RatioLossP/E (Static)207.13MShares8.88052wk High-3.35P/B1.46BFloat Cap4.03052wk Low--Dividend TTM193.23MShs Float37.250Historical High--Div YieldTTM4.74%Amplitude0.600Historical Low7.512Avg Price1Lot Size
About BioCryst Pharmaceuticals Company
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Company Profile
SymbolBCRX
Company NameBioCryst Pharmaceuticals
Listing DateMar 3, 1994
Issue Price6.50
Founded1986
CEOMr. Jon P. Stonehouse
MarketNASDAQ
Employees536
Fiscal Year Ends12-31
Address4505 Emperor Boulevard,Suite 200
CityDurham
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27703-8457
Phone1-919-859-1302
Websitehttp://www.biocryst.com
Company Executives
- Name
- Position
- Salary
- Jon P. Stonehouse
- Director, President and Chief Executive Officer
- 4.78M
- Dr. Helen M. Thackray, M.D.
- Chief Research and Development Officer
- 2.39M
- Anthony Doyle
- Chief Financial Officer, Treasurer and Interim Principal Accounting Officer
- 1.79M
- Alane Barnes
- Chief Legal Officer and Corporate Secretary
- 1.93M
- Charles K. Gayer
- Chief Commercial Officer
- 1.74M
- Dr. Nancy J. Hutson, PhD
- Chairman of the Board
- 470.30K
- Stephen J. Aselage
- Independent Director
- 446.90K
- Vincent J. Milano
- Independent Director
- 434.82K
- George B. Abercrombie
- Independent Director
- 432.74K
- Dr. Amy McKee
- Independent Director
- 422.32K
- Machelle Sanders
- Independent Director
- 423.15K
- Dr. Steven Galson, M.D.
- Independent Director
- 424.40K
- Alan G. Levin
- Independent Director
- 434.54K
- Theresa M. Heggie
- Independent Director
- 433.57K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.